Safety and Efficacy Study of a Dual Pi3k Delta/Gamma Inhibitor in T-Cell Lymphoma

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Purpose
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Website: https://clinicaltrials.gov/ct2/show/NCT02567656?term=NCT02567656&rank=1

Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 

Please refer to this study by its ClinicalTrials.gov identifier: NCT02567656

Contacts
Contact: Auris Huen, MD    713 745- 1113    aohuen@mdanderson.org    
Contact: Yasuhiro Oki, MD    713 792- 2860    yoki@@mdanderson.org

Sponsors and Collaborators
Rhizen Pharmaceuticals SA

Locations

United States, Texas
MD Anderson Cancer Center    Recruiting
Houston, Texas, United States, 77030
Contact: Carol Wilson, R.N., B.S.    713-563-4655    clwilson@mdanderson.org   
Contact: Alda Ashu, BSN, RN, OCN    713-563-3559    abmiraso@mdanderson.org